<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655629</url>
  </required_header>
  <id_info>
    <org_study_id>12094</org_study_id>
    <nct_id>NCT00655629</nct_id>
  </id_info>
  <brief_title>Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.</brief_title>
  <official_title>Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety and efficacy of a new dosage form of Vardenafil, an
      orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo
      (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase,
      patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be
      determined by laboratory and other evaluations. Efficacy will be determined by the results of
      different questionnaires and the patient diary that will be used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF)</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <description>The primary variable was the treatment group difference from baseline to Week 12 or LOCF of the least square mean difference in the IIEF-EF domain score (Range: 1-30 ordinal. Directionality: severity of erectile dysfunction: &lt;=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; &gt;25 'no ED'.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage From Baseline in Success of Penetration (SEP2) at 12 Weeks</measure>
    <time_frame>from baseline up to 12 weeks of treatment</time_frame>
    <description>SEP (Sexual Encounter Profile) items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to penetrate the partner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Success of Erection Maintenance at 12 Weeks</measure>
    <time_frame>from baseline up to 12 weeks of treatment</time_frame>
    <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to maintain an erection after penetration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving &quot;Back to Normal&quot; Erectile Function</measure>
    <time_frame>up to 12 weeks of treatment</time_frame>
    <description>Responders: percentage of subjects achieving an IIEF-EF score &gt; 25. The primary variable was the treatment group difference from baseline to Week 12 or Last observation carried forward (LOCF) of the least square mean difference in the IIEF-EF domain score (1-30 ordinal points, specifying the severity of erectile dysfunction: &lt;=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; &gt;25 'no ED').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage From Baseline in Ability to Obtain an Erection at 12 Weeks</measure>
    <time_frame>from baseline up to 12 weeks of treatment</time_frame>
    <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to obtain successful erections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage From Baseline in Satisfaction With the Hardness of Erection at 12 Weeks</measure>
    <time_frame>from baseline up to 12 weeks of treatment</time_frame>
    <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to get satisfactory hardness of erections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage From Baseline in Overall Satisfaction at 12 Weeks</measure>
    <time_frame>from baseline up to 12 weeks of treatment</time_frame>
    <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to overall satisfactory attempts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage From Baseline in Ability to Ejaculate at 12 Weeks</measure>
    <time_frame>from baseline up to 12 weeks of treatment</time_frame>
    <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to have successful ejaculations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Sexual Attempts Till First Successful Attempt</measure>
    <time_frame>up to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ease With Erection at 12 Weeks or LOCF</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Ease with Erection&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erectile Function Satisfaction at 12 Weeks or LOCF</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Erectile function satisfaction&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pleasure of Sexual Activity at 12 Weeks or LOCF</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Pleasure of sexual activity&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Satisfaction With Orgasm at 12 Weeks or LOCF</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Satisfaction with orgasm&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Confidence for Completion at 12 Weeks or LOCF</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
    <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Confidence for completion&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Medication at Week 12 or LOCF</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Satisfaction with medication&quot; at LOCF expressed as the least square mean difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Self Reported Improvement of Erectile Function Under Treatment Using a Categorical Rating Scale</measure>
    <time_frame>up to 12 weeks of treatment</time_frame>
    <description>Categorical Rating Scale is a binary rating scale with 2 response options which is 'yes/no'; percentage of participants with positive answers to the Global Assessment Question. Global Assessment Question (GAQ): 'Has the treatment you have been taking over the past for weeks improved your erection?' (yes/no)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Vardenafil ODT (STAXYN, BAY38-9456)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vardenafil ODT (STAXYN, BAY38-9456)</intervention_name>
    <description>Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)</description>
    <arm_group_label>Vardenafil ODT (STAXYN, BAY38-9456)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 18 years-of-age or older.

          -  Stable, heterosexual relationship for at least 6 months.

          -  A history of erectile dysfunction (ED) for at least 6 months

        Exclusion Criteria:

          -  Any underlying cardiovascular condition, including unstable angina pectoris

          -  History of myocardial infarction, stroke or life-threatening arrhythmia within 6
             months prior to visit 1

          -  Uncontrolled atrial fibrillation / flutter at screening

          -  History of congenital QT prolongation

          -  History of surgical prostatectomy due to prostate cancer

          -  Hereditary degenerative retinal disorders

          -  History of loss of vision because of NAION (Non-arteritic anterior ischemic optic
             neuropathy), temporary or permanent loss of vision

          -  Presence of penile anatomical abnormalities

          -  Spinal cord injury

          -  Resting or postural hypotension or hypertension

          -  Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens,
             alpha-blockers, HIV (Human immunodeficiency virus) protease inhibitors, itraconazole
             or ketoconazole, and clarithromycin and erythromycin.

          -  Subjects taking medication known to prolong QT interval, such as Type Ia and Type 3
             anti-arrhythmics.

          -  Subjects who have been confirmed with phenylketonuria (PKU).

          -  Use of any treatment for ED within 7 days of Visit 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Valley Family Physicians, PLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mesa Family Medical Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Clinical Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tatum Highlands Medical Associates, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiel Family &amp; Sports Medicine, PC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618-3603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Uro-Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Impotence Treatment Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research, Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Bruce Gilbert, MD</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212-2787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Urology Research, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Associates</name>
      <address>
        <city>Levittown</city>
        <state>Pennsylvania</state>
        <zip>19056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Clinical Research</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Roger Fincher, MD</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Men's Health</name>
      <address>
        <city>Bondi Junction</city>
        <state>New South Wales</state>
        <zip>2022</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berry Road Medical Centre</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Terrace Urology</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Medical Centre</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perth Human Sexuality Centre</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Joseph's Health Care-London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Rajiv Singal, MD</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique d'Urologie du Saguenay</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 4A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology South Shore Research</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche en Sante Sexuelle du Quebec</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dalinde</name>
      <address>
        <city>México, D. F.</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Dr. Rodríguez Rivera</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico de las Américas</name>
      <address>
        <city>Mérida</city>
        <state>Yucatán</state>
        <zip>97001</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociación Mexicana para la Salud Sexual A. C.</name>
      <address>
        <city>México D. F.</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Fé</name>
      <address>
        <city>México, D. F.</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <results_reference>
    <citation>Debruyne FM, Gittelman M, Sperling H, Börner M, Beneke M. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med. 2011 Oct;8(10):2912-23. doi: 10.1111/j.1743-6109.2011.02462.x. Epub 2011 Aug 30.</citation>
    <PMID>21883954</PMID>
  </results_reference>
  <results_reference>
    <citation>Gittelman M, McMahon CG, Rodríguez-Rivera JA, Beneke M, Ulbrich E, Ewald S. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract. 2010 Apr;64(5):594-603. doi: 10.1111/j.1742-1241.2010.02358.x.</citation>
    <PMID>20456213</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>October 7, 2010</results_first_submitted>
  <results_first_submitted_qc>December 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2011</results_first_posted>
  <disposition_first_submitted>February 8, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 8, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 10, 2010</disposition_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited to 35 investigational centers in the USA (20), Canada (4), Mexico (5), and Australia (6). First patient first visit on 28 Apr 2008, last patient last visit on 13 Feb 2009.</recruitment_details>
      <pre_assignment_details>473 subjects screened (&lt;65 years: n=230; &gt;=65 years: n=243), 339 randomized (Vardenafil 10 mg ODT=172, placebo=167). The main efficacy analysis set was the ITT (Intent to Treat) population (randomized treated sub. with baseline and post-baseline in any of the efficacy variables and safety assessment); Vardenafil 10 mg ODT=169, placebo=162</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
          <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="171">1 patient could not verify drug ingestion. (safety population)</participants>
                <participants group_id="P2" count="166">1 patient could not verify drug ingestion.(safety population)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
          <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="337"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="4.4"/>
                    <measurement group_id="B2" value="28.7" spread="4.2"/>
                    <measurement group_id="B3" value="28.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF)</title>
        <description>The primary variable was the treatment group difference from baseline to Week 12 or LOCF of the least square mean difference in the IIEF-EF domain score (Range: 1-30 ordinal. Directionality: severity of erectile dysfunction: &lt;=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; &gt;25 'no ED'.)</description>
        <time_frame>from baseline up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF)</title>
          <description>The primary variable was the treatment group difference from baseline to Week 12 or LOCF of the least square mean difference in the IIEF-EF domain score (Range: 1-30 ordinal. Directionality: severity of erectile dysfunction: &lt;=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; &gt;25 'no ED'.)</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="7.78"/>
                    <measurement group_id="O2" value="1.7" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="8.06"/>
                    <measurement group_id="O2" value="1.1" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="8.11"/>
                    <measurement group_id="O2" value="1.4" spread="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Power adjustment for 3 primary efficacy variables (3 variables have to be significant in favor of Vardenafil to conclude efficacy). Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.45</ci_lower_limit>
            <ci_upper_limit>-5.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage From Baseline in Success of Penetration (SEP2) at 12 Weeks</title>
        <description>SEP (Sexual Encounter Profile) items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to penetrate the partner.</description>
        <time_frame>from baseline up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage From Baseline in Success of Penetration (SEP2) at 12 Weeks</title>
          <description>SEP (Sexual Encounter Profile) items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to penetrate the partner.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of successful penetrations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="33.27"/>
                    <measurement group_id="O2" value="4.6" spread="34.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="37.39"/>
                    <measurement group_id="O2" value="3.0" spread="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="35.40"/>
                    <measurement group_id="O2" value="3.8" spread="33.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-25.972</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-32.688</ci_lower_limit>
            <ci_upper_limit>-19.256</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Success of Erection Maintenance at 12 Weeks</title>
        <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to maintain an erection after penetration.</description>
        <time_frame>from baseline up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Success of Erection Maintenance at 12 Weeks</title>
          <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to maintain an erection after penetration.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of successful maintenance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="33.22"/>
                    <measurement group_id="O2" value="15.2" spread="29.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="38.32"/>
                    <measurement group_id="O2" value="8.7" spread="29.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="36.47"/>
                    <measurement group_id="O2" value="12.0" spread="29.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.432</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-40.439</ci_lower_limit>
            <ci_upper_limit>-26.425</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving &quot;Back to Normal&quot; Erectile Function</title>
        <description>Responders: percentage of subjects achieving an IIEF-EF score &gt; 25. The primary variable was the treatment group difference from baseline to Week 12 or Last observation carried forward (LOCF) of the least square mean difference in the IIEF-EF domain score (1-30 ordinal points, specifying the severity of erectile dysfunction: &lt;=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; &gt;25 'no ED').</description>
        <time_frame>up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving &quot;Back to Normal&quot; Erectile Function</title>
          <description>Responders: percentage of subjects achieving an IIEF-EF score &gt; 25. The primary variable was the treatment group difference from baseline to Week 12 or Last observation carried forward (LOCF) of the least square mean difference in the IIEF-EF domain score (1-30 ordinal points, specifying the severity of erectile dysfunction: &lt;=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; &gt;25 'no ED').</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH adjusted for age group and center</method_desc>
            <param_type>Cochran-Mantel-Haenszel</param_type>
            <param_value>53.8693</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage From Baseline in Ability to Obtain an Erection at 12 Weeks</title>
        <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to obtain successful erections.</description>
        <time_frame>from baseline up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage From Baseline in Ability to Obtain an Erection at 12 Weeks</title>
          <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to obtain successful erections.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of successful erections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="28.63"/>
                    <measurement group_id="O2" value="-5.8" spread="38.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="35.96"/>
                    <measurement group_id="O2" value="-3.8" spread="37.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="32.46"/>
                    <measurement group_id="O2" value="-4.8" spread="37.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.41</ci_lower_limit>
            <ci_upper_limit>-9.746</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage From Baseline in Satisfaction With the Hardness of Erection at 12 Weeks</title>
        <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to get satisfactory hardness of erections.</description>
        <time_frame>from baseline up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage From Baseline in Satisfaction With the Hardness of Erection at 12 Weeks</title>
          <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to get satisfactory hardness of erections.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of satisfactory erections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="40.04"/>
                    <measurement group_id="O2" value="12.2" spread="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="41.54"/>
                    <measurement group_id="O2" value="5.4" spread="31.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="41.45"/>
                    <measurement group_id="O2" value="8.8" spread="31.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.134</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-40.281</ci_lower_limit>
            <ci_upper_limit>-25.987</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage From Baseline in Overall Satisfaction at 12 Weeks</title>
        <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to overall satisfactory attempts.</description>
        <time_frame>from baseline up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage From Baseline in Overall Satisfaction at 12 Weeks</title>
          <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to overall satisfactory attempts.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of satisfactory attempts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="40.04"/>
                    <measurement group_id="O2" value="12.2" spread="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="38.43"/>
                    <measurement group_id="O2" value="10.3" spread="26.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="40.15"/>
                    <measurement group_id="O2" value="11.2" spread="26.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.934</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-41.119</ci_lower_limit>
            <ci_upper_limit>-26.749</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage From Baseline in Ability to Ejaculate at 12 Weeks</title>
        <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to have successful ejaculations.</description>
        <time_frame>from baseline up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage From Baseline in Ability to Ejaculate at 12 Weeks</title>
          <description>SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to have successful ejaculations.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of ejaculation successes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="32.52"/>
                    <measurement group_id="O2" value="7.1" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="36.27"/>
                    <measurement group_id="O2" value="2.7" spread="36.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="35.72"/>
                    <measurement group_id="O2" value="4.9" spread="35.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-20.902</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.724</ci_lower_limit>
            <ci_upper_limit>-14.081</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Sexual Attempts Till First Successful Attempt</title>
        <time_frame>up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Sexual Attempts Till First Successful Attempt</title>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>Sexual Attempts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.7"/>
                    <measurement group_id="O2" value="2.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="4.5"/>
                    <measurement group_id="O2" value="3.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="4.1"/>
                    <measurement group_id="O2" value="3.1" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ease With Erection at 12 Weeks or LOCF</title>
        <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Ease with Erection&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference.</description>
        <time_frame>from baseline up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ease With Erection at 12 Weeks or LOCF</title>
          <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Ease with Erection&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference.</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="34.29"/>
                    <measurement group_id="O2" value="6.1" spread="31.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="29.17"/>
                    <measurement group_id="O2" value="0.0" spread="27.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="32.07"/>
                    <measurement group_id="O2" value="3.0" spread="29.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.866</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.599</ci_lower_limit>
            <ci_upper_limit>-11.133</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erectile Function Satisfaction at 12 Weeks or LOCF</title>
        <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Erectile function satisfaction&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
        <time_frame>from baseline up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erectile Function Satisfaction at 12 Weeks or LOCF</title>
          <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Erectile function satisfaction&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="27.78"/>
                    <measurement group_id="O2" value="7.6" spread="24.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="26.11"/>
                    <measurement group_id="O2" value="4.2" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="28.01"/>
                    <measurement group_id="O2" value="5.9" spread="24.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-26.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-31.547</ci_lower_limit>
            <ci_upper_limit>-20.533</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pleasure of Sexual Activity at 12 Weeks or LOCF</title>
        <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Pleasure of sexual activity&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
        <time_frame>from baseline up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pleasure of Sexual Activity at 12 Weeks or LOCF</title>
          <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Pleasure of sexual activity&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="24.63"/>
                    <measurement group_id="O2" value="4.8" spread="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="29.63"/>
                    <measurement group_id="O2" value="-1.9" spread="22.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="28.19"/>
                    <measurement group_id="O2" value="1.4" spread="24.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.496</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.676</ci_lower_limit>
            <ci_upper_limit>-14.315</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Satisfaction With Orgasm at 12 Weeks or LOCF</title>
        <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Satisfaction with orgasm&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
        <time_frame>from baseline up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Satisfaction With Orgasm at 12 Weeks or LOCF</title>
          <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Satisfaction with orgasm&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="30.81"/>
                    <measurement group_id="O2" value="3.2" spread="31.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.418</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.439</ci_lower_limit>
            <ci_upper_limit>-12.396</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Confidence for Completion at 12 Weeks or LOCF</title>
        <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Confidence for completion&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
        <time_frame>from baseline up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Confidence for Completion at 12 Weeks or LOCF</title>
          <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Confidence for completion&quot; from baseline to Week 12 or LOCF expressed as the least square mean difference</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" spread="28.59"/>
                    <measurement group_id="O2" value="4.8" spread="28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="27.74"/>
                    <measurement group_id="O2" value="2.8" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="29.46"/>
                    <measurement group_id="O2" value="3.8" spread="27.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.379</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.006</ci_lower_limit>
            <ci_upper_limit>-16.753</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Medication at Week 12 or LOCF</title>
        <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Satisfaction with medication&quot; at LOCF expressed as the least square mean difference</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with LOCF values.</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Medication at Week 12 or LOCF</title>
          <description>Treatment group difference in points on the Treatment Satisfaction Scale (TSS: 0-100 normalized, ordinal; Directionality: Higher scores indicate greater levels of (i) ease with erection, (ii) erectile functioning satisfaction, (iii) pleasure of sexual activity, (iv) satisfaction with orgasm, (v) confidence for completion, and (vi) satisfaction with medication.) domain &quot;Satisfaction with medication&quot; at LOCF expressed as the least square mean difference</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with LOCF values.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="26.55"/>
                    <measurement group_id="O2" value="19.3" spread="26.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="30.26"/>
                    <measurement group_id="O2" value="20.2" spread="24.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="29.52"/>
                    <measurement group_id="O2" value="19.7" spread="25.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-30.758</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-36.736</ci_lower_limit>
            <ci_upper_limit>-24.779</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Self Reported Improvement of Erectile Function Under Treatment Using a Categorical Rating Scale</title>
        <description>Categorical Rating Scale is a binary rating scale with 2 response options which is 'yes/no'; percentage of participants with positive answers to the Global Assessment Question. Global Assessment Question (GAQ): 'Has the treatment you have been taking over the past for weeks improved your erection?' (yes/no)</description>
        <time_frame>up to 12 weeks of treatment</time_frame>
        <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
            <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Self Reported Improvement of Erectile Function Under Treatment Using a Categorical Rating Scale</title>
          <description>Categorical Rating Scale is a binary rating scale with 2 response options which is 'yes/no'; percentage of participants with positive answers to the Global Assessment Question. Global Assessment Question (GAQ): 'Has the treatment you have been taking over the past for weeks improved your erection?' (yes/no)</description>
          <population>The primary data set was the ITT (Intent-to treat) population defined as all randomized treated subjects with baseline and post-baseline efficacy data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to the total population.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH adjusted for age group and center</method_desc>
            <param_type>Cochran-Mantel-Haenszel</param_type>
            <param_value>60.2391</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vardenafil ODT (STAXYN, BAY38-9456)</title>
          <description>Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bacterial rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Penis deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pharmaceutical product complaint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the protocol it is specified that all results are the property of the sponsor. The investigator must discuss any publication with the sponsor prior to release and obtain written consent of the sponsor. The investigator must send a draft publication to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

